Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AE 37

Drug Profile

AE 37

Alternative Names: AE37; AE37 peptide/GM-CSF HER2 peptide vaccine; AE37 vaccine; Cancer vaccine AE37 - Generex-Biotechnology; Cancer vaccine AE37 - NuGenerex Imuuno-Oncology; Cancer vaccine HER2/neu Antigen Express AE37; Cancer vaccine HER2/neu Generex Biotechnology AE37; Her-2/neu Breast cancer; Her-2/neu Prostate cancer; Ii-key hybrid cancer vaccine AE37; Ii-key hybrid HER2/neu vaccine Antigen Express AE37; Ii-key hybrid HER2/neu vaccine Generex Biotechnology AE37; Ii-Key/Her-2/neu(776-790) vaccine; Modified HER2/neu peptide AE37 vaccine

Latest Information Update: 24 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antigen Express
  • Developer Antigen Express; Merck AG; NSABP Foundation; NuGenerex Immuno-Oncology
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants; Regulatory T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Prostate cancer
  • Discontinued Ovarian cancer

Most Recent Events

  • 15 Oct 2019 Generex Biotechnology completes a phase IIb trial for Breast cancer (Prevention) in USA, Germany and Greece (NCT00524277) (EudraCT2007-000934-38)
  • 15 Oct 2019 Generex Biotechnology plans a clinical trials for Urogenital cancer, Prostate cancer, Bladder cancer and Renal cell carcinoma (Combination therapy)
  • 03 May 2019 Phase-II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA (Intradermal) (NCT04024800)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top